Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Chris Lange | Aug 20, 2015 at 11:15 AM EDT

Eli Lilly Continues to Rise on Positive Jardiance Results

Eli Lilly shares got a solid boost in the market Thursday morning as the broad markets were selling off.

Chris Lange | Aug 20, 2015 at 10:25 AM EDT

Applied Genetic Solidifies Deal With Biogen

Applied Genetic Technologies announced that the Biogen equity investment as part of their collaboration has closed.

Lee Jackson | Aug 20, 2015 at 8:20 AM EDT

Big Catalysts Coming Within a Week for 2 Specialty Pharmaceutical Stocks

ThinkstockWith biotech and specialty pharmaceutical stocks, catalysts and binary events can drive the stocks much higher, or in some cases…

Paul Ausick | Aug 20, 2015 at 7:35 AM EDT

Is Valeant About to Buy Maker of Female Viagra?

The Wall Street Journal reported Thursday morning that Canada-based Valeant Pharmaceuticals is preparing to pay $1 billion for the closely…

Chris Lange | Aug 19, 2015 at 11:05 AM EDT

How a Fast Track Designation Saved Corbus Pharma

Corbus Pharmaceuticals may have found its saving grace in a Fast Track designation from the U.S. Food and Drug Administration…

Paul Ausick | Aug 19, 2015 at 7:55 AM EDT

Will Sprout Pharmaceuticals Go Public?

Privately held start-up Sprout Pharmaceuticals received FDA approval on Tuesday for its flibanserin pill with the trade name Addyi.

Chris Lange | Aug 18, 2015 at 11:47 AM EDT

Omeros Shares Doubling on Positive Phase 2 Data

ThinkstockOmeros Corp. (NASDAQ: OMER) is flying high in Tuesday’s trading session with shares practically doubling on positive phase 2 news.…

Chris Lange | Aug 18, 2015 at 8:56 AM EDT

Esperion Updates Phase 2 Study and Keeps Volatility Traders Interested

ThinkstockEsperion Therapeutics, Inc. (NASDAQ: ESPR) had a huge move in Monday’s trading session as the result of an analyst upgrade…

Lee Jackson | Aug 18, 2015 at 8:22 AM EDT

4 Top Pharma Stocks That Should Outperform Out To 2016

ThinkstockWith a very nervous market, and the end of summer doldrums upon us, it may be time to look for…

Chris Lange | Aug 17, 2015 at 4:45 PM EDT

Aclaris Gets Ready For Its Initial Public Offering

ThinkstockAclaris Therapeutics, Inc. filed an S-1 form with the Securities and Exchange Commission (SEC) for its initial public offering (IPO).…

Paul Ausick | Aug 17, 2015 at 4:43 PM EDT

Agilent Beats on Profits, but Guidance Does Not Match Analyst Expectations

ThinkstockAgilent Technologies Inc. (NYSE: A) reported third fiscal quarter 2015 earnings after markets closed Monday. For the quarter, healthcare company…

Jon C. Ogg | Aug 17, 2015 at 4:31 PM EDT

What the Cord Blood Registry Buyout Really Adds to AMAG

ThinkstockAMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) had already seen shares rise handily prior to the summer selloff. While this deal is…

Chris Lange | Aug 17, 2015 at 2:45 PM EDT

SynCardia Prepares For IPO

Thinkstock Medical device maker SynCardia Systems, Inc. filed an S-1 form with the Securities and Exchange Commission (SEC) for its initial…

Chris Lange | Aug 17, 2015 at 10:20 AM EDT

Kite Pharma Updates Study, Dispells Rumors

Kite Pharma gave an update from its ongoing Phase 1/2 clinical trial of KTE-C19 in patients with refractory aggressive non-Hodgkin's…

Chris Lange | Aug 17, 2015 at 9:45 AM EDT

Is AVEO the Next Aquinox for Traders?

Aveo Pharmaceuticals made waves in early trading indications Monday on news of a licensing agreement with Novartis.

1 … 249 250 251 252 253 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Eli Lilly Continues to Rise on Positive Jardiance Results

Applied Genetic Solidifies Deal With Biogen

Big Catalysts Coming Within a Week for 2 Specialty Pharmaceutical Stocks

Is Valeant About to Buy Maker of Female Viagra?

How a Fast Track Designation Saved Corbus Pharma

Will Sprout Pharmaceuticals Go Public?

Omeros Shares Doubling on Positive Phase 2 Data

Esperion Updates Phase 2 Study and Keeps Volatility Traders Interested

4 Top Pharma Stocks That Should Outperform Out To 2016

Aclaris Gets Ready For Its Initial Public Offering

Agilent Beats on Profits, but Guidance Does Not Match Analyst Expectations

What the Cord Blood Registry Buyout Really Adds to AMAG

SynCardia Prepares For IPO

Kite Pharma Updates Study, Dispells Rumors

Is AVEO the Next Aquinox for Traders?

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125%

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Health and Healthcare Articles

All Health and Healthcare Articles

Eli Lilly Continues to Rise on Positive Jardiance Results

Applied Genetic Solidifies Deal With Biogen

Big Catalysts Coming Within a Week for 2 Specialty Pharmaceutical Stocks

Is Valeant About to Buy Maker of Female Viagra?

How a Fast Track Designation Saved Corbus Pharma

Will Sprout Pharmaceuticals Go Public?

Omeros Shares Doubling on Positive Phase 2 Data

Esperion Updates Phase 2 Study and Keeps Volatility Traders Interested

4 Top Pharma Stocks That Should Outperform Out To 2016

Aclaris Gets Ready For Its Initial Public Offering

Agilent Beats on Profits, but Guidance Does Not Match Analyst Expectations

What the Cord Blood Registry Buyout Really Adds to AMAG

SynCardia Prepares For IPO

Kite Pharma Updates Study, Dispells Rumors

Is AVEO the Next Aquinox for Traders?

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125%

Featured Reads

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how